JY
CRDL

Jeff Yass’s Cardiol Therapeutics CRDL Stock Holding History

Jeff Yass’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.3K Buy
+25,800
New +$32.7K ﹤0.01% 12985
2024
Q3 		– Sell
-133,000
Closed -$269K – 12121
2024
Q2 		$269K Buy
133,000
+95,000
+250% +$202K ﹤0.01% 9693
2024
Q1 		$68.8K Buy
38,000
+20,600
+118% +$27.8K ﹤0.01% 11422
2023
Q4 		$14.6K Buy
+17,400
New +$14.8K ﹤0.01% 12022
2022
Q2 		– Sell
-87,000
Closed -$134K – 13015
2022
Q1 		$134K Sell
87,000
-30,300
-26% -$50K ﹤0.01% 11663
2021
Q4 		$217K Buy
+117,300
New +$324K ﹤0.01% 11266

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jeff Yass's CRDL Position: Q2 2026 in Review

Jeff Yass sold out of Cardiol Therapeutics (CRDL) in Q2 2026, closing a stake of 70,396 shares — an estimated $89.1K sold.

Jeff Yass first reported a position in CRDL in Q1 2022 and held it in 13 quarters. The position peaked at $194K in Q4 2025. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Jeff Yass reported no remaining Cardiol Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 70,396 Cardiol Therapeutics shares in Q2 2026, an estimated $89.1K.
  • Jeff Yass first reported a position in Cardiol Therapeutics in Q1 2022 and held it in 13 quarters.
  • Jeff Yass's Cardiol Therapeutics position peaked at $194K in Q4 2025.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.